Clinical Trials on ACL Reconstruction

Total 437015 results

The Affiliated Hospital of the Chinese Academy...
Chinese PLA General Hospital

Unknown

Allogeneic CART-33 for Relapsed/Refractory CD33+ AML

Relapsed and/or Refractory CD33+ AML

China
Karolinska University Hospital

Completed

Photochemotherapy and Graft-versus-leukemia in Acute-leukemia

AML | ALL | Acute GVHD | Tumor Immunity

Sweden
Samsung Medical Center
Ministry of Health, Republic of Korea

Recruiting

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Relapsed Pediatric AML | Refractory Pediatric AML | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid Tumor

Korea, Republic of
ETH Zurich
University of Zurich

Not yet recruiting

Pharmacoscopy-guided Clinical Standard-of-care in r/r AML (RAPID-01)

AML, Adult
Stichting Hemato-Oncologie voor Volwassenen Nederland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients (HO155)

AML/MDS

Netherlands, Belgium, Germany, Switzerland
The University of Hong Kong

Recruiting

Oral Arsenic Trioxide for NPM1-mutated AML

NPMc+ AML

Hong Kong
Ramsay Générale de Santé
European Clinical Trial Experts Network; Private Hospital Jean Mermoz

Recruiting

Risk of Osteoarthritis of the Knee at Least 5 Years After ACL Reconstruction: Comparative Study Between an Isolated ACL Reconstruction and a Reconstruction Combining ACL and ALL

Knee Injuries | ACL | ALL | Anterior Curciate Ligament | Anterolateral Ligament

France
Nantes University Hospital

Completed

Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) (Cloric)

AML | MDS | ALL | BAL

France
Rigshospitalet, Denmark
Groupe Hospitalier Pitie-Salpetriere

Completed

Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects (Bezafibrate)

Carnitine Palmitoyltransferase II Deficiency | Very Long Chain Acyl Coa Dehydrogenase Deficiency

Denmark
Brigham and Women's Hospital
Arthritis Foundation

Recruiting

Preventing Injured Knees From osteoArthritis: Severity Outcomes (PIKASO)

Osteoarthritis, Knee | Post-traumatic Osteoarthritis | ACL Tear

United States
Matthew Varacallo
Pacira Biosciences

Not yet recruiting

Impact of Opioid Avoidance Protocol for ACL Reconstruction

Post Operative Pain | ACL Tear

United States
Tartu University Hospital

Recruiting

Kinesiophobia After Anterior Cruciate Ligament Reconstruction.

ACL Injury | Kinesiophobia

Estonia
University Hospital, Caen
INSERM U1075 COMETE, UNICAEN, Caen France

Completed

Isokinetic Muscular Assessment After ACL Ligamentoplasty: Study of Factors Predictive of Muscle Imbalance. (PREDICT-ACL)

Muscle Weakness | ACL - Anterior Cruciate Ligament Deficiency

France
Istituto Scientifico Romagnolo per lo Studio e...

Unknown

Italian Non-Interventional Study of FLT3 Mutated AML Patients (FLAM)

AML | FLT3-ITD Mutation | FLT3-TKD Mutation

Italy
National Taiwan University Hospital

Unknown

PCL (Poly-ε-caprolactone) Mesh Pleurodesis

PCL Pleurodesis
Actinium Pharmaceuticals

Recruiting

Venetoclax and Lintuzumab-Ac225 in AML Patients

Acute Myeloid Leukemia | Relapsed Adult AML

United States
University Hospital, Caen
INSERM U1075 COMETE, UNICAEN, Caen France

Completed

Hamstring Stiffness After Anterior Cruciate Ligament Reconstruction (ACLSTIFF)

Sport Injury | ACL Injury | Stiffness of Knee, Not Elsewhere Classified

France
Elucida Oncology
Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL)

Withdrawn

ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML (Pediatric AML)

Acute Myeloid Leukemia | AML, Childhood | Relapsed Pediatric AML | Refractory Pediatric AML
The First Affiliated Hospital of Soochow University

Not yet recruiting

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Relapsed/Refractory AML

China
University Hospital Inselspital, Berne

Recruiting

Drug-screening in AML at Relapse for Targeted Treatment (DARTT-1)

AML

Switzerland
Centre Antoine Lacassagne
Acute Leukemia French Association

Not yet recruiting

A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML (AGORA-1)

AML
Actinium Pharmaceuticals

Withdrawn

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Acute Myeloid Leukemia | Relapsed Adult AML
University of Pittsburgh
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation

Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency

United States
Chen Suning

Active, not recruiting

Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

Chemotherapy Effect | AML, Adult

China
University Hospital Inselspital, Berne

Withdrawn

Epacadostat, Cladribine and Cytarabine (ECC) in AML (ECC)

AML | Relapse

Switzerland
Chinese PLA General Hospital
Navy General Hospital, Beijing

Unknown

Chidamide Plus DCAG for Relapsed/Refractory AML

AML | Relapse

China
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Completed

Phase I Study in RAD 001 Patients With Relapse AML

AML

France
Istituto Ortopedico Rizzoli

Completed

Effect of Biophysical Stimulation on Intraspongious Bone Edema in Anterior Cruciate Ligament Reconstruction

Pain | ACL Injury | Magnetic Field Exposure

Italy
Grupo Argentino de Tratamiento de la Leucemia Aguda

Completed

Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia

AML | Pediatric AML
Groupe Francophone des Myelodysplasies
AbbVie

Recruiting

Venetoclax in Patients With MDS or AML in Relapse After AHSCT

AML | MDS

France
University of Minnesota

Completed

Systemic Markers of Inflammation: 9- and 12-Month Follow-Up Post Non-Surgical Periodontal Therapy

Biomarkers | SRP | Minocycline HCl Microspheres

United States
Nordic MDS Group

Completed

Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5

AML | MDS

Denmark, Norway, Sweden
MacroGenics

Terminated

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) (VOYAGE)

AML

United States, United Kingdom, Germany, Israel, Spain, France, Italy, Netherlands
University of Wisconsin, Madison

Terminated

FLT-PET Imaging for MDS

AML | MDS

United States
Merck Sharp & Dohme LLC

Terminated

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)

DLBCL | AML Including AML de Novo and AML Secondary to MDS
Sports Surgery Clinic, Santry, Dublin

Recruiting

What is the Effect of Vision on Movement Control in Anterior Cruciate Ligament Reconstructed Patients 7 Months Post-surgery?

ACL

Ireland
University of Pittsburgh

Completed

ACL-reconstruction vs ACL-reconstruction With EAT

ACL

United States
TScan Therapeutics, Inc.

Recruiting

A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation

Myelodysplastic Syndromes | AML | ALL, Adult

United States
AvenCell Europe GmbH
GCP-Service International Ltd. & Co. KG

Terminated

Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Relapsed AML | Refractory AML

Germany
Maximilian Stahl, MD
Syndax Pharmaceuticals

Not yet recruiting

Revumenib in Combination With 7+3 + Midostaurin in AML

Acute Myeloid Leukemia | Leukemia | AML | AML, Adult | AML With Gene Mutations

United States
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS

AML | MDS

China
Aptevo Research and Development LLC

Recruiting

Study of APVO436 in Patients With AML or MDS

AML | MDS

United States
French Innovative Leukemia Organisation
Acute Leukemia French Association

Recruiting

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (OGILAR)

AML, Adult | Relapsed Adult AML | Refractory AML | FLT3-TKD Mutation | FLT3-ITD

France
Goethe University

Completed

Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)

AML

Germany
The Second Hospital of Shandong University

Not yet recruiting

NK Cell Therapy Recurrent/Refractory Elderly AML

AML | Elderly | Recurrent | Refractory

China
Mana Therapeutics

Terminated

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT

AML/MDS

United States
Celyad Oncology SA
IQVIA Biotech

Completed

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 (DEPLETHINK)

AML | MDS

United States, Belgium
Saint Joseph Mercy Health System

Completed

EMail Reminder to Follow up With Primary Physician

Act Code - Emergency
Agios Pharmaceuticals, Inc.

Approved for marketing

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Acute Myeloid Leukemia | Relapsed Pediatric AML | Relapsed Adult AML
Daiichi Sankyo, Inc.

Completed

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

AML

United States, Korea, Republic of, Taiwan, United Kingdom, France, Australia, Spain, Italy, Canada, Singapore, Germany, Netherlands, Hong Kong, Belgium, Croatia, Czechia, Hungary, Poland, Serbia

Clinical Trials on ACL Reconstruction

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations